Former AXA Framlington Biotechnology fund manager Andy Smith has joined biopharma specialist Mann Bioinvest to launch an income-focused fund in the coming weeks.
The Magna BioPharma Income fund, slated to launch around the end of Q1 2013, will be managed by Smith, with key decisions overseen by an investment committee. Boutique equity house Charlemagne Capital...
Joined with 21 Partners
Consequences could be more severe than in stress tests
Move to variable operating expenses
Set to happen on 4 April